Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations

• Published in: Cancer research (Chicago, Ill.) Vol. 48; no. 8; pp. 2029 - 2035
• Main Authors: CHOY, B. K, MCCLARTY, G. A, CHAN, A. K, THELANDER, L, WRIGHT, J. A
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.04.1988
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Cell Line; DNA - analysis; Dose-Response Relationship, Drug; Drug Resistance; Electron Spin Resonance Spectroscopy; General aspects; Hydroxyurea - pharmacology; Medical sciences; Mice; Mutation; Pharmacology. Drug treatments; Ribonucleotide Reductases - analysis; Ribonucleotide Reductases - genetics; Ribonucleotide Reductases - physiology; RNA, Messenger - analysis; Transcription, Genetic; Antineoplastic agent; Cell cloning; Enzyme; Rodentia; EPR spectrometry; In vitro; Mechanism; Resistance; Vertebrata; Mammalia; Ribonucleotide reductase; Mouse; Animal; Immunoblotting assay; Tumor cell
• ISSN: 0008-5472; 1538-7445

Mammalian ribonucleotide reductase is a highly regulated, rate-limiting activity responsible for converting ribonucleoside diphosphates to the deoxyribonucleotide precursors of DNA. The enzyme consists of two nonidentical proteins often called M1 and M2, both of which are required for activity. Hydroxyurea is an antitumor agent which inhibits ribonucleotide reductase by interacting with the M2 component specifically at a unique tyrosyl free radical. To obtain further information about drug resistance mechanisms, we have used M1 and M2 complementary DNAs and monoclonal antibodies to investigate the properties of a series of clonally related drug-resistant mouse cell lines, selected by a step-wise procedure for increasing levels of resistance to the cytotoxic effects of hydroxyurea. Several interesting mechanisms have been identified. Each successive drug selection step leading to the isolation of highly resistant cells was accompanied by stable elevations in cellular resistance and ribonucleotide reductase activities. The changes that occurred at each step involved the M2 component. A very early event, occurring at the first step in the selection process, was the amplification of the M2 gene accompanied by an increase in M2 messenger RNA. Although cellular resistance and M2 protein levels increased significantly during drug selection, only a modest change in M2 gene copy number was observed after the initial selection step. Analysis of wild type, moderately resistant, and highly resistant cells indicated that, in addition to M2 gene amplification, posttranscriptional modification also occurred during drug selection. This second mechanism was not due to alterations in protein M2 half-life, but involved an increase in translational efficiency. By increasing the rate of M2 synthesis, without altering degradation rates, resistant cells were able to accumulate high levels of this key regulatory protein. Cells selected for the ability to proliferate in concentrations of drug as high as 4 mM exhibited changes that involved M2, without detectable changes to M1. These results provide further evidence that M1 and M2 levels are controlled by different mechanisms in mammalian cells. Eventually, however, cells required an elevation in the M1 protein, as well as the M2 protein, to survive in a hydroxyurea concentration of 5 mM. These results illustrate the complexity of the drug-resistant phenotype and provide further information about the molecular processes that lead to the development of cells resistant to low, intermediate, and high concentrations of hydroxyurea.